Table 1.

Association between PARP1 gene polymorphisms and neuroblastoma risk

Genotype	Cases (N=469)	Controls (N=998)	P a	Crude OR (95% CI)	P	Adjusted OR (95% CI) b	P b
rs1136410 (HWE=0.669)
AA	136 (29.00)	330 (33.07)		1.00		1.00
AG	244 (52.03)	482 (48.30)		1.23 (0.96-1.58)	0.110	1.23 (0.95-1.58)	0.116
GG	89 (18.98)	186 (18.64)		1.16 (0.84-1.60)	0.363	1.17 (0.84-1.61)	0.353
Additive			0.276	1.09 (0.94-1.28)	0.260	1.10 (0.94-1.28)	0.255
Dominant	333 (71.00)	668 (66.93)	0.119	1.21 (0.95-1.54)	0.119	1.21 (0.95-1.53)	0.122
Recessive	380 (81.02)	812 (81.36)	0.877	1.02 (0.77-1.35)	0.876	1.03 (0.78-1.36)	0.846
rs2666428 (HWE=0.569)
TT	305 (65.03)	636 (63.73)		1.00		1.00
TC	149 (31.77)	325 (32.57)		0.96 (0.75-1.21)	0.710	0.96 (0.75-1.21)	0.712
CC	15 (3.20)	37 (3.71)		0.85 (0.46-1.56)	0.593	0.85 (0.46-1.57)	0.600
Additive			0.827	0.94 (0.77-1.15)	0.561	0.94 (0.77-1.15)	0.566
Dominant	164 (34.97)	362 (36.27)	0.627	0.95 (0.75-1.19)	0.628	0.95 (0.75-1.19)	0.631
Recessive	454 (96.80)	961 (96.29)	0.623	0.86 (0.47-1.58)	0.623	0.86 (0.47-1.59)	0.630
rs8679 (HWE=0.256)
AA	407 (86.78)	871 (87.27)		1.00		1.00
AG	60 (12.79)	125 (12.53)		1.03 (0.74-1.43)	0.873	1.03 (0.74-1.43)	0.872
GG	2 (0.43)	2 (0.20)		2.14 (0.30-15.25)	0.448	2.18 (0.31-15.55)	0.437
Additive			0.732	1.06 (0.78-1.45)	0.710	1.06 (0.78-1.46)	0.705
Dominant	62 (13.22)	127 (12.73)	0.792	1.05 (0.76-1.45)	0.791	1.05 (0.75-1.45)	0.789
Recessive	467 (99.57)	996 (99.80)	0.439	2.13 (0.30-15.19)	0.450	2.17 (0.31-15.49)	0.438
Combined effect of risk genotypes c
0-1	115 (24.52)	281 (28.16)		1.00		1.00
2-3	354 (75.48)	717 (71.84)	0.144	1.21 (0.94-1.55)	0.144	1.21 (0.94-1.55)	0.148

OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium.

^a χ² test for genotype distributions between neuroblastoma patients and cancer-free controls.

^b Adjusted for age and gender.

^c Risk genotypes were rs1136410 AG/GG, rs2666428 TC/TT and rs8679 AG/GG.